Guardant, a biotechnology company, provides a blood test on Guardant’s Smart Liquid Biopsy platform that uses epigenomic analysis to detect circulating tumor DNA to predict GI cancer recurrence, according to a Jan. 21 news release.
The Guardant Reveal test is now covered by Medicare for use in the CRC surveillance setting after curative intent treatment. Previously, coverage expanded only to testing for CRC in the early post-surgical setting.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
